Important Safety Information
ELIGARD should not be used by women, children, or anyone who is allergic to the
drug leuprolide acetate or any of the ingredients of ELIGARD. Leuprolide acetate
can cause harm to the fetus if given to a pregnant woman.
ELIGARD, like other drugs in its class, causes a temporary increase in testosterone
during the first and second weeks of treatment. Patients may experience worsening
of symptoms or new symptoms during the first weeks of treatment, including bone
pain, nerve damage, blood in the urine, pressure on the spine, or difficulty urinating.
If your cancer has spread to the spine or urinary tract, urinary blockage or pressure
in the spine may occur and can sometimes lead to paralysis, which may be fatal.
You may require close medical attention during the first few weeks of therapy and
you should notify your doctor if you develop any new or worsened symptoms after
beginning treatment with ELIGARD.
The most common injection site side effects are temporary burning and stinging,
pain, bruising and redness. The most common systemic adverse events include mild
to severe hot flashes/sweats, fatigue, weakness, fever, muscle pain, testicular
shrinkage and breast enlargement. For more information on these and other side effects,
please talk to your doctor.
Indication
ELIGARD is a prescription drug, given by injection, for the management of advanced
prostate cancer. However, there is no known cure for prostate cancer.
Please see and full mixing and administration instructions.
Click here
for information on drug anti-counterfeiting.